Works matching Hepatitis treatment

Results: 5000
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26

    Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan.

    Published in:
    Hepatology Research, 2010, v. 40, n. 1, p. 8, doi. 10.1111/j.1872-034X.2009.00634.x
    By:
    • Kumada, Hiromitsu;
    • Okanoue, Takeshi;
    • Onji, Morikazu;
    • Moriwaki, Hisataka;
    • Izumi, Namiki;
    • Tanaka, Eiji;
    • Chayama, Kazuaki;
    • Sakisaka, Shotaro;
    • Takehara, Tetsuo;
    • Oketani, Makoto;
    • Suzuki, Fumitaka;
    • Toyota, Joji;
    • Nomura, Hideyuki;
    • Yoshioka, Kentaro;
    • Seike, Masataka;
    • Yotsuyanagi, Hiroshi;
    • Ueno, Yoshiyuki
    Publication type:
    Article
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.

    Published in:
    PLoS ONE, 2018, v. 13, n. 4, p. 1, doi. 10.1371/journal.pone.0194704
    By:
    • Mashiba, Toshie;
    • Joko, Kouji;
    • Kurosaki, Masayuki;
    • Ochi, Hironori;
    • Osaki, Yukio;
    • Kojima, Yuji;
    • Nakata, Ryo;
    • Goto, Tohru;
    • Takehiro, Akahane;
    • Kimura, Hiroyuki;
    • Mitsuda, Akeri;
    • Kawanami, Chiharu;
    • Uchida, Yasushi;
    • Ogawa, Chikara;
    • Kusakabe, Atsunori;
    • Narita, Ryuichi;
    • Ide, Yasushi;
    • Abe, Takehiko;
    • Tsuji, Keiji;
    • Kitamura, Tadashi
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43
    44

    The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus‐infected people who inject drugs in England.

    Published in:
    Addiction, 2019, v. 114, n. 6, p. 1113, doi. 10.1111/add.14569
    By:
    • Harrison, Graham I.;
    • Murray, Karen;
    • Gore, Roxanne;
    • Lee, Penelope;
    • Sreedharan, Aravamuthan;
    • Richardson, Paul;
    • Hughes, Amanda J.;
    • Wiselka, Martin;
    • Gelson, Will;
    • Unitt, Esther;
    • Ratcliff, Karen;
    • Orton, Annette;
    • Trinder, Kerry;
    • Simpson, Charlotte;
    • Ryder, Stephen D.;
    • Oelbaum, Sandra;
    • Foster, Graham R.;
    • Christian, Archie;
    • Smith, Stuart;
    • Thomson, Brian J.
    Publication type:
    Article
    45
    46
    47
    48

    Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection.

    Published in:
    Clinical Infectious Diseases, 2014, v. 59, n. 12, p. 1657, doi. 10.1093/cid/ciu696
    By:
    • Howe, Anita Y. M.;
    • Black, Stuart;
    • Curry, Stephanie;
    • Ludmerer, Steven W.;
    • Liu, Rong;
    • Barnard, Richard J. O.;
    • Newhard, William;
    • Hwang, Peggy M. T.;
    • Nickle, David;
    • Gilbert, Christopher;
    • Caro, Luzelena;
    • DiNubile, Mark J.;
    • Mobashery, Niloufar
    Publication type:
    Article
    49
    50